Pronutria names new CMO
This article was originally published in Scrip
Cambridge, Massachusetts-based Pronutria Biosciences, a biotechnology company developing a new class of therapeutics to mediate amino acid biology, has named Dr Christopher Wright senior vice-president and chief medical officer. Dr Wright will lead the company's global clinical development and medical affairs. Prior to joining Pronutria Biosciences, he was senior vice-president and head of global medicine development and affairs at Vertex Pharmaceuticals, where he led global development functions across all therapeutic areas of clinical development, medical affairs, clinical operations, medical writing, biometrics, regulatory affairs and patient safety.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.